Nasal administration of interleukin‐33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate
- 8 March 2016
- journal article
- Published by Wiley in Immunology
- Vol. 148 (1), 83-91
- https://doi.org/10.1111/imm.12589
Abstract
The T-helper cell type 2-promoting cytokine interleukin-33 (IL-33) has been implicated in asthma pathogenesis. Angiogenesis is a feature of airways remodelling in asthma. We hypothesized that IL-33 induces airways angiogenesis and expression of angiogenic factors in an established murine surrogate of asthma. In the present study, BALB/c mice were subjected to serial intranasal challenge with IL-33 alone for up to 70 days. In parallel, ovalbumin (OVA) -sensitized mice were subjected to serial intranasal challenge with OVA or normal saline to serve as positive and negative controls, respectively. Immunohistochemical analysis of expression of von Willebrand factor and erythroblast transformation-specific-related gene, both blood vessel markers, and angiogenic factors angiogenin, insulin-like growth factor-1, endothelin-1, epidermal growth factor and amphiregulin was performed in lung sections ex vivo. An established in-house assay was used to test whether IL-33 was able to induce microvessel formation by human vascular endothelial cells. Results showed that serial intranasal challenge of mice with IL-33 or OVA resulted in proliferation of peribronchial von Willebrand factor-positive blood vessels to a degree closely related to the total expression of the angiogenic factors amphiregulin, angiogenin, endothelin-1, epidermal growth factor and insulin-like growth factor-1. IL-33 also induced microvessel formation by human endothelial cells in a concentration-dependent fashion in vitro. Our data are consistent with the hypothesis that IL-33 has the capacity to induce angiogenesis at least partly by increasing local expression of multiple angiogenic factors in an allergen-independent murine asthma surrogate, and consequently that IL-33 or its receptor is a potential novel molecular target for asthma therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81471594, 81373177)
This publication has 38 references indexed in Scilit:
- Angiogenesis in bronchial asthmaInternational Journal of Immunopathology and Pharmacology, 2015
- Direct comparison of the dynamics of IL-25- and ‘allergen’-induced airways inflammation, remodelling and hypersensitivity in a murine asthma modelClinical and Experimental Allergy, 2014
- A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitisThe Journal of Experimental Medicine, 2013
- IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the LungsThe Journal of Immunology, 2012
- Increased IL-33 expression by epithelial cells in bronchial asthmaJournal of Allergy and Clinical Immunology, 2010
- Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic LoadJournal of the American College of Cardiology, 2008
- Nuclear Interleukin-33 Is Generally Expressed in Resting Endothelium but Rapidly Lost upon Angiogenic or Proinflammatory ActivationThe American Journal of Pathology, 2008
- Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune systemInternational Immunology, 2008
- Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesisOncogene, 2004
- Prolonged allergen challenge in mice leads to persistent airway remodellingClinical and Experimental Allergy, 2004